Medipharm Labs (TSX: LABS) is launching its first branded products to the Canadian marketplace. This morning, the company announced that it has launched its own line of products for consumption in the medical and recreational cannabis markets, beginning with CBD-focused oil.
The first product to launch, referred to as the CBD Regular Formula 25, is a 25:1 CBD to THC product that uses coconut oil as its carrier oil. Additional products are stated to follow the launch of the CBD oil in the coming weeks, in varied potencies and product formats. The company indicated that it intends to soon offer gel cap and topical products as well under its medical line.
Medipharm appears to be largely targeting the medical consumer first, with this mornings release containing a long spiel about its focus on the 1.1 million medical cannabis users in Canada. It appears that the company largely intends to reach those users by launching it’s medical line on the Medical Cannabis by Shoppers platform.
Medipharm Labs last traded at $2.27 on the TSX.
Information for this briefing was found via Sedar and Medipharm Labs. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.